Sponsors (28)
The bill seeks to expand federal support for antimicrobial R&D, availability, stewardship, and preparedness—improving care and national readiness—while increasing government spending and creating risks of administrative complexity, higher drug prices, and allocation tradeoffs between military and civilian needs.
Patients (including those with chronic conditions) and hospitals will gain more reliable access to effective antimicrobials and new clinical tools to prevent and treat drug‑resistant infections.
Researchers and scientists will receive increased federal support that could accelerate development of new antibiotics, diagnostics, and related therapies.
Clinicians and health systems will have an increased focus on appropriate use and stewardship that can slow antimicrobial resistance and improve patient safety over time.
Taxpayers could face higher federal spending to support R&D, procurement, or programs created by the bill.
Patients could see higher drug prices if the law’s measures favor private firms or do not preserve price protections.
Hospitals, clinicians, and state public‑health agencies may face new regulatory, procurement, or administrative burdens and complexity to implement the programs.
Based on analysis of 3 sections of legislative text.
Adds a new Title III Public Health Service program to promote development, access, stewardship, and preparedness for antimicrobials (substantive details not included in excerpt).
Official title: To amend the Public Health Service Act to establish a program to develop innovative antimicrobial drugs targeting the most challenging pathogens and most threatening infections, and for other purposes.
Introduced February 4, 2026 by Buddy Carter · Last progress February 4, 2026
Creates a new Public Health Service provision to promote development, market access, appropriate use, and preparedness for lifesaving antimicrobials by adding a "Developing antimicrobial innovations" program to Title III of the Public Health Service Act. The Act's stated goals include stimulating research and access to new antimicrobials, preserving appropriate clinical use, maintaining high standards of care, strengthening national health preparedness, and supporting defense and military health needs. The bill text provided only shows the short title, purpose statement, and that a new provision is appended to Title III; substantive program details, funding, deadlines, and implementation language are not included in the excerpt, so operational effects depend on the content of the inserted provision not shown here.